Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > New Hires ...

<< Previous

Bullboard Posts

Next >>

Comment by bringon10baggeron Nov 25, 2020 11:03am

210 Views

Post# 31969534

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Hires ...

here's the link.........

Unmet Medical Need: Millions of Americans Could Benefit from Next-Generation NSAIDs | 2020-11-24 | Press Releases | Stockhouse

AntibeTribe wrote: I'm curious as to which companies you're looking at there, 10bag?

bringon10bagger wrote: Very interesting to compare other Naz listed biotech/pharma company all in early phase developments, all 3 have market caps between 1.6-2.2 billion and Antibe heading to phase III, with a MC of 150M, now that's a gross disparity.........we'll take a 1.6B mc for $4/share...........positioning to expect at some point.

bringon10bagger wrote: Unmet Medical Need: Millions of Americans Could Benefit from Next-Generation NSAIDs | 2020-11-24 | Press Releases | Stockhouse

MrMugsy wrote: Exactly ... we have allocated the funds ($5M) for the dosing part of P3.
We are good to start.
We still have lots of negotiating work to get to our goal of partnering for Phase 3.

There are still a lot of R&D developments and FDA administrative work to follow (and hopefully good news from that) ... before we get to Phase 3.

Excitement should build as we attempt to partner.

Anything can happen - or not happen !

Hahaha !